{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:21:46Z","timestamp":1790709706330,"version":"4.1.0"},"reference-count":69,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n                    Ketamine has emerged as a putative rapid-acting treatment option for psychiatric disorders, particularly treatment-resistant depression. Chronic recreational ketamine use is associated with ketamine-induced urological toxicity, raising concerns over the safety of repeated ketamine treatments. This systematic review aimed to synthesise urological findings from clinical trials and observational studies using ketamine for the treatment of psychiatric disorders. Electronic databases were searched up until 4th April 2024 for trials and observational studies using ketamine treatment for psychiatric disorders in adults, and which reported assessment of urinary, bladder or renal symptoms. Twenty-seven studies were included, mostly in depressive disorders (\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    \u2009=\u200924). Urological symptoms were reported in 0%\u201324.5% of patients receiving ketamine treatment; symptoms tended to be mild or moderate in severity. Where reported, continuous outcome measures (urinary parameters and symptom questionnaires) did not show significant changes from baseline to follow-up. Only 15% of studies were rated low risk of bias. Most studies did not assess long-term ketamine treatment, and many included undefined or passive monitoring of urological symptoms rather than systematic assessment. Based on the limited data available, ketamine treatment does not appear to be associated with elevated risk of urological symptoms; however, further long-term studies are required.\n                  <\/jats:p>","DOI":"10.1177\/02698811251350267","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T03:20:32Z","timestamp":1751253632000},"page":"1103-1113","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-8307","authenticated-orcid":false,"given":"Jess","family":"Kerr-Gaffney","sequence":"first","affiliation":[{"name":"Department of Psychological Medicine, Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9835-0900","authenticated-orcid":false,"given":"Anna","family":"Tr\u00f6ger","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"},{"name":"Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus at the TU-Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6033-7527","authenticated-orcid":false,"given":"Alice","family":"Caulfield","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ritter","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"},{"name":"Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus at the TU-Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4647-8088","authenticated-orcid":false,"given":"James","family":"Rucker","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000717"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11634"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.52965\/001c.38247"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17f11738"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000894"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-021-00734-5"},{"key":"e_1_3_3_8_1","unstructured":"atai Life Sciences (2023) atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression. Available at: https:\/\/atai.life\/2023\/01\/09\/atai-life-sciences-announces-results-from-phase-2a-trial-of-pcn-101-r-ketamine-for-treatment-resistant-depression\/ (accessed 13 January 2025)."},{"key":"e_1_3_3_9_1","first-page":"346","article-title":"Ketamine role in schizoaffective disorder depressive type","volume":"8","author":"Aziz W","year":"2017","unstructured":"Aziz W, Babb C, Brown D, et al. (2017) Ketamine role in schizoaffective disorder depressive type. J Addict Res Ther 8: 346.","journal-title":"J Addict Res Ther"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.09.071"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.4787"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Berman RM Cappiello A Anand A et al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351\u2013354. https:\/\/doi.org\/10.1016\/S0006-3223(99)00230-9","DOI":"10.1016\/S0006-3223(99)00230-9"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.05.028"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01230-z"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0365-0"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.12.038"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3739"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1189"},{"key":"e_1_3_3_19_1","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder","volume":"9","author":"Dean RL","year":"2021","unstructured":"Dean RL, Hurducas C, Hawton K, et al. (2021) Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev 9: CD011612.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1980.10471430"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01116-3"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0256-5"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20050596"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.62"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz039"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-021-01260-4"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05611-y"},{"key":"e_1_3_3_28_1","unstructured":"Food and Drug Administration (2023) FDA warns patients and health care providers about potential risks associated with compounded ketamine products including oral formulations for the treatment of psychiatric disorders. Available at: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine (accessed 20 April 2025)."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118760660"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2017.06.007"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118762073"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2021.21030277"},{"key":"e_1_3_3_33_1","first-page":"1232","article-title":"A pediatric case of ketamine-associated cystitis","volume":"71","author":"Gr\u00e9goire MC","year":"2008","unstructured":"Gr\u00e9goire MC, MacLellan DL, Finley GA (2008) A pediatric case of ketamine-associated cystitis. Urology 71: 1232\u20131233.","journal-title":"Urology"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4786-3"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113935"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.338"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(73)71306-2"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1997.10400185"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2007.10399860"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.03.026"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.02.151"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2023.79"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12572"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/91.7.493"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0572-3"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03576.x"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyae046"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.01.024"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13030392"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.06.022"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05767-1"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.10.008"},{"key":"e_1_3_3_53_1","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. (2021) PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ; 372: n160.","journal-title":"BMJ"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2023-300870"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40337-023-00751-w"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304145"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2015.10.032"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.07.089"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30272-9"},{"key":"e_1_3_3_61_1","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. (2016) ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ; 355: i4919.","journal-title":"BMJ"},{"key":"e_1_3_3_62_1","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovic J, Page M, et al. (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366: l4898.","journal-title":"BMJ"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216309106828"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891"},{"key":"e_1_3_3_65_1","first-page":"1","article-title":"Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review","volume":"8","author":"Walsh Z","year":"2022","unstructured":"Walsh Z, Mollaahmetoglu OM, Rootman J, et al. (2022) Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review. BJPsych Open 8: 1\u201312.","journal-title":"BJPsych Open"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-4679(00)00162-1"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11028.x"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.10031.x"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01577-5"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.015198"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251350267","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251350267","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251350267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:18Z","timestamp":1777507938000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251350267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/02698811251350267"],"URL":"https:\/\/doi.org\/10.1177\/02698811251350267","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}